A practical reference on chronic hepatitis B: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-18 and is reviewed periodically as new material appears.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
In 2020, Chen Xiaojiang was appointed as head of the National Ethnic Affairs Commission, the first Han Chinese head of the body since 1954. On 24 June 2022, Pan Yue, another Han Chinese, became the head of the commission, with him reportedly holding assimilationist policies toward ethnic minorities. Xi outlined his official views relations between the majority Han Chinese and ethnic minorities by saying "[n]either Han chauvinism nor local ethnic chauvinism is conducive to the development of a community for the Chinese nation." Xi's policies toward ethnic minorities were codified in the Law on Promoting Ethnic Unity and Progress in 2026.
NPU terminology (NPU; Nomenclature for Properties and Units) is a patient-centered clinical laboratory terminology for use in the clinical laboratory sciences. Its function is to enable results of clinical laboratory examinations to be used safely across technology, time and geography. To achieve this, the NPU terminology supplies:
The Weismann barrier, proposed by August Weismann in 1892, distinguishes between the "immortal" germ cell lineages (the germ plasm) which produce gametes and the "disposable" somatic cells. Hereditary information moves only from germline cells to somatic cells (that is, somatic mutations are not inherited). This, before the discovery of the role or structure of DNA, does not predict the central dogma, but does anticipate its gene-centric view of life, albeit in non-molecular terms.
Aspirin Ibuprofen (Advil, Nurofen) Naproxen (Aleve) There are several potential pharmacokinetic interactions between the various individual SSRIs and other medications. Most of these arise from the fact that every SSRI can inhibit certain P450 cytochrome enzymes.
Datopotamab deruxtecan, sold under the brand name Datroway, is an anti-cancer medication used for the treatment of breast cancer. It is a Trop-2-directed antibody and topoisomerase inhibitor antibody-drug conjugate. The most common adverse reactions, including laboratory abnormalities, include stomatitis, nausea, fatigue, decreased leukocytes, decreased calcium, alopecia, decreased lymphocytes, decreased hemoglobin, constipation, decreased neutrophils, dry eye, vomiting, increased ALT, keratitis, increased AST, and increased alkaline phosphatase. Datopotamab deruxtecan was approved for medical use in the United States in January 2025, and in the European Union in April 2025.
Sources: en.wikipedia.org
imperial, as imperialist invaders that attacked the essence of being Ecuadorian and that frustrated the Realm of Quito, through the interference of its neighbor to the south (whether as Incas or as a Peruvian viceroyalty) in the historical development of the construction of the nation. The military forces, pressured by the conflict with Peru, have developed their own defense and national security doctrine. The notions of sovereignty, integrity and national unity have been a hard core in the military imaginary that would ideologically influence the white and mestizo elite of the modern Ecuadorian nation-state. After the Cenepa War and the signing of a definitive peace, it has been claimed that the Ecuadorian State has a duty to change the teaching of the history of its country, eliminating from school textbooks the multiple elements of anti-Peruvianism that have been taught for decades. future generations of the country, putting an end to the falsehoods that distorted the Ecuadorian national consciousness, to improve Ecuador-Peru Relations. The vision of Ecuadorians about Peruvians was analyzed by Durán Barba in 1992. The results obtained, from a national sample, showed that the majority of those surveyed considered that Ecuadorians are more intelligent, hard-working, courageous, prepared and honest; as well as less violent and false than the Peruvians. Most of those questioned denounced a bias of preferring to trade with people from Colombia than with those from Peru.
=== The Healing Foundation === In 1998, as Treasurer of the British Association of Plastic, Reconstructive, and Aesthetic Surgeons (BAPRAS), Brough and his fellow Trustees established The Healing Foundation. Building on the groundwork laid by the Phoenix Appeal, The Healing Foundation aimed to advance research into surgical and psychological healing techniques for individuals with disfiguring conditions. Various UK medical membership bodies provided support to The Healing Foundation as Partner Member Organisations. These partnerships bolstered the charity's credibility, networking capabilities, and financial resources.These organisations were BAPRAS, the British Association of Aesthetic Surgeons, the British Psychological Society, the Craniofacial Society of Great Britain and Ireland, the British Burns Association, and the British Society for Surgery of the Hand.
Ado Jimada Gana Muhammad OON (born 18 January 1967) is a Nigerian medical doctor and public health administrator who serves as Global Programme Director of the D-8 Health and Social Protection Programme. He previously served as the Executive Director/CEO of the Nigeria's National Primary Health Care Development Agency (NPHCDA), the government agency responsible for developing national primary health care (PHC) policy and supporting states and local government areas (LGAs) to implement them. Muhammad was appointed to that position on 1 November 2011, by the administration of President Goodluck Jonathan. Prior to his appointment, Muhammad served as a special assistant to the permanent secretary, in the State House, Abuja. Muhammad succeeded Muhammad Ali Pate who was appointed as the Minister of State for Health in 2011.
=== Social Security === On March 18, 2025, the Social Security Administration announced they would be implementing tighter identity requirements starting March 31, with this date pushed forward to April 14. The new policy requires takes away the telephone option and requires individuals to either apply online or appear in-person at a field office. Applications for SSDI, Medicare, or SSI are exempted from this in-person requirement, along with applicants subject to extreme situations "such as terminal cases or prisoner pre-release scenarios". This new policy comes at a time the Trump administration is closing some field offices and laying off some Social Security staff. In late March, Wired reported that DOGE was putting together a team to migrate the Social Security base code from COBOL to a more modern programming language, with the goal of achieving this in a matter of months, whereas most experts say it should take several years to do and test this safely. It was reported in mid-April that the Trump administration had placed on the "Death Master File", renamed the "Ineligible Master File", more than 6,000 persons who are legal immigrants whom officials claim are either on a terrorism watch list or have an FBI criminal record. The White House, however, did not provide evidence for this claim. Social Security will "clawback" money from a disabled or retired person's monthly payments in cases in which overpayments are discovered.
Sources: en.wikipedia.org
=== Termination === Macrolides and clindamycin (both also having other potential mechanisms) cause premature dissociation of the peptidyl-tRNA from the ribosome. Puromycin has a structure similar to that of the tyrosinyl aminoacyl-tRNA. Thus, it binds to the ribosomal A site and participates in peptide bond formation, producing peptidyl-puromycin. However, it does not engage in translocation and quickly dissociates from the ribosome, causing a premature termination of polypeptide synthesis. Streptogramins also cause premature release of the peptide chain.
Leprecan (also called prolyl 3-hydroxylase 1) is an enzyme which in humans is encoded by the gene P3H1. Certain mutations in the gene have been associated with osteogenesis imperfecta type VIII. Leprecan is part of a superfamily of 2OG-Fe(II) dioxygenase, along with DNA repair protein AlkB, and disease resistant EGL-9. The enzyme was found to be a type of hydroxylases used in the substrate formation of protein glycosylation.
The vaginal plate is the precursor to the vagina. During development, the vaginal plate begins to grow where the fused ends of the paramesonephric ducts (Müllerian ducts) enter the back wall of the urogenital sinus as the sinus tubercle. As the plate grows, it significantly separates the cervix and the urogenital sinus; eventually, the central cells of the plate break down to form the vaginal lumen. This usually occurs by the twenty to twenty-fourth week of development. If the lumen does not form, or is incomplete, membranes known as vaginal septa can form across or around the tract, causing obstruction of the outflow tract later in life. There are conflicting views on the embryologic origin of the vagina. The majority view is Koff's 1933 description, which posits that the upper two-thirds of the vagina originate from the caudal part of the Müllerian duct, while the lower part of the vagina develops from the urogenital sinus. Other views are Bulmer's 1957 description that the vaginal epithelium derives solely from the urogenital sinus epithelium, and Witschi's 1970 research, which reexamined Koff's description and concluded that the sinovaginal bulbs are the same as the lower portions of the Wolffian ducts. Witschi's view is supported by research by Acién et al., Bok and Drews. Robboy et al. reviewed Koff and Bulmer's theories, and support Bulmer's description in light of their own research. The debates stem from the complexity of the interrelated tissues and the absence of an animal model that matches human vaginal development.
Indium has 39 known isotopes, ranging in mass number from 97 to 135. Only two isotopes occur naturally as primordial nuclides: indium-113, the only stable isotope, and indium-115, which has a half-life of 4.41×1014 years, four orders of magnitude greater than the age of the Universe and nearly 30,000 times greater than half-life of thorium-232. The half-life of 115In is very long because the beta decay to 115Sn is spin-forbidden. Indium-115 makes up 95.7% of all indium. Indium is one of three known elements (the others being tellurium and rhenium) of which the stable isotope is less abundant in nature than the long-lived primordial radioisotopes. The stablest artificial isotope is indium-111, with a half-life of approximately 2.8 days. All other isotopes have half-lives shorter than 5 hours. Indium also has 47 meta states, among which indium-114m1 (half-life about 49.51 days) is the most stable, more stable than the ground state of any indium isotope other than the primordial. All decay by isomeric transition. The indium isotopes lighter than 113In predominantly decay through electron capture or positron emission to form cadmium isotopes, while the indium isotopes heavier than 113In predominantly decay through beta-minus decay to form tin isotopes.
Animals, not humans, serve as reservoir species for rabies and are responsible for passing the virus to humans in the overwhelming majority of cases. Therefore to eliminate rabies in an area is to eliminate rabies from the local animal populations, both wild and domestic. Pre-exposure immunization has been used on domesticated and wild populations. In many jurisdictions, domestic dogs, cats, ferrets, and rabbits are required to be vaccinated.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.